Every drug company wants to get the best price for its drugs, but that's easier said than done, especially in the current environment with payers pushing back at high drug prices and pitting companies against each other to compete on price. Read More
Biotechs are still flying through the IPO window, albeit in slightly smaller numbers than a year ago. Through June, 31 IPOs generated $2.95 billion, approximately $300 million more than was raised in the first half of last year. (See BioWorld Insight, July 6, 2015.) Read More
